Andy Studna, Senior Editor

Howell shares important insights from the most recent J.P. Morgan Healthcare Conference and addresses where the clinical trials industry currently is with innovation.

In an interview with ACT editor Andy Studna, Jim Reilly, VP, R&D Strategy, Veeva Systems, discusses ways stakeholders can select the best solutions available in clinical trials.

Recent study tests the ability of machine learning to effectively classify patient safety event reports.

The FDA has cleared an investigational new drug application and granted Fast Track designation to ACDN-01, the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses the Summit for Clinical Ops Executives (SCOPE) conferences in Europe and the US.

Survey of over 100 industry professionals measured opinions on future research within the therapeutic area of obesity treatment.

Conducted by Onward Therapeutics, the trial will evaluate a bispecific antibody generated from Biomunex’s BiXAb platform.

Data from prior Phase II study showed signs of pridopidine slowing disease progression in patients with amyotrophic lateral sclerosis.

Micah Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and what attendees can expect at SCOPE.

Baig discusses the challenges she is currently seeing with connecting sites as well as how they can keep pace with new technologies.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and how the need to create it came about.

Utility Therapeutics’ pivmecillinam is an oral antibiotic for the treatment of uncomplicated urinary tract infections.

With $13 million grant, Vanderbilt University Medical Center will lead the new multisite trial.

New analysis for 2023 shows signs of post-pandemic recovery; breast cancer remains most studied disease area.

Study examines how many registered clinical trials with published protocols are also publishing their results.

Clinical study identifies combination of 11 proteins that can predict long-term disability in patients with multiple sclerosis.

Utilizing known processes and managing risks are among best practices with new technologies, such as artificial intelligence, according to Gottlieb.

Flo Mowlem, VP of Science at ObvioHealth discusses digital study design—touching on how to best manage data and medical devices.

Effects of newly implemented NIH policy on data sharing could be profound for clinical research.

Verma discusses the use of technology and data to increase clinical trial access.

Industry has urgent need for an objective system that evaluates the efficacy of AI tools in clinical settings.

Authors highlighted outsourcing and the impact of the COVID-19 pandemic in these CRO/sponsor articles from 2023.

Industry experts touched on patient needs, rare diseases, and gender analysis among other topics in these written Q&As.

Applied Clinical Trials sat down on-site with many KOLs at some of industry's largest gatherings in 2023 including SCOPE, DIA, and DPHARM.

Throughout 2023, guests of the Applied Clinical Trials podcast spoke on a number of topics including clinical research in rare disease areas, data, and artificial intelligence.

Authors in this area focused on increasing diversity in clinical trials through patient-first payment options and trial design.

Parents of children with cancer and limited health literacy were associated with lower comprehension of informed consent.

In an interview with ACT editor, Andy Studna, Hesterlee, Chief Research Officer at the Muscular Dystrophy Association discusses a new therapy for Duchenne Muscular Dystrophy, Vamorolone, and what sets it apart from other therapies in the market.

An evolving payer and commercial landscape post-COVID-19 pandemic, increasing regulatory complexity, and the discovery of new treatments with smaller patient populations are all factors impacting the research, development, and launch of new pharmaceutical products.

Women within underserved populations with an endometrial, ovarian, or cervical cancer diagnosis were found to be underrepresented in trials.